

## REFERENCES

- American Cancer Society. (2013). *Cancer Facts & Figures 2013*.
- Andayani, T. M. (2013). *Farmakoekonomi: Prinsip dan Metodologi*. Bursa Ilmu.
- ASCO. (2022, September). *Head and Neck Cancer: Types of Treatment*. Cancer.Net. <https://www.cancer.net/cancer-types/head-and-neck-cancer/types-treatment#main-content>
- Bansal, A., Singh, M., & Rai, B. (2016). Human papillomavirus-associated cancers: A growing global problem. *International Journal of Applied and Basic Medical Research*, 6(2), 84. <https://doi.org/10.4103/2229-516X.179027>
- Bardach, A. E., Garay, O. U., Calderón, M., Pichón-Riviére, A., Augustovski, F., Martí, S. G., Cortiñas, P., Gonzalez, M., Naranjo, L. T., Gomez, J. A., & Caporale, J. E. (2017). Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. *BMC Public Health*, 17(1), 152. <https://doi.org/10.1186/s12889-017-4064-7>
- Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M.-P., & Hill, S. R. (2016). Cost-effectiveness thresholds: Pros and cons. *Bulletin of the World Health Organization*, 94(12), 925–930. <https://doi.org/10.2471/BLT.15.164418>
- BPJS Kesehatan. (2021). *MEDIA INFO BPJS KESEHATAN EDISI 104*. <https://bpjs-kesehatan.go.id/bpjs-dmdocuments/ae3544d7f3382ebb639eba99192b5c76.pdf>
- Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J., Gomez, D., Munoz, J., Bosch, F. X., & de Sanjose, S. (2021). *ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Indonesia*.
- Bruni, L., Albero, G., Serrano, B., Mena, M., Collado, J., Gomez, D., Munoz, J., Bosch, F. X., & de Sanjose, S. (2023). *ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World*. <https://hpvcentre.net/statistics/reports/XWX.pdf>
- Burbure, N., Handorf, E., Ridge, J. A., Bauman, J., Liu, J. C., Giri, A., & Galloway, T. J. (2021). Prognostic significance of HPV status and treatment modality in hypopharyngeal cancer. *Head & Neck*, 43(10), 3042–3052. <https://doi.org/10.1002/hed.26793>

- Burger, E. A., Sy, S., Nygård, M., Kristiansen, I. S., & Kim, J. J. (2014). Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys. *PLoS ONE*, 9(3), e89974. <https://doi.org/10.1371/journal.pone.0089974>
- Cancer Registry, F. U. (2020, January 1). *Laporan Regisrrasi Kanker Berbasis Rumah Sakit periode Januari 2020 di RSUP Dr. Sardjito*. <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/januari-2020/>
- Carta, A., & Conversano, C. (2020). On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers. *Frontiers in Public Health*, 8, 569500. <https://doi.org/10.3389/fpubh.2020.569500>
- CDC. (2021, November 16). *Human Papillomavirus (HPV) Vaccination: What Everyone Should Know*. <https://www.cdc.gov/vaccines/vpd/hpv/public/index.html>
- Chaturvedi, A. K., Graubard, B. I., Broutian, T., Xiao, W., Pickard, R. K. L., Kahle, L., & Gillison, M. L. (2019). Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. *JAMA*, 322(10), 977–979. <https://doi.org/10.1001/jama.2019.10508>
- Chen, S., Cao, Z., Prettnner, K., Kuhn, M., Yang, J., Jiao, L., Wang, Z., Li, W., Geldsetzer, P., Bärnighausen, T., Bloom, D. E., & Wang, C. (2023). Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050. *JAMA Oncology*, 9(4), 465. <https://doi.org/10.1001/jamaoncol.2022.7826>
- Choi, S. E., Choudhary, A., Huang, J., Sonis, S., Giuliano, A. R., & Villa, A. (2022). Increasing HPV vaccination coverage to prevent oropharyngeal cancer: A cost-effectiveness analysis. *Tumour Virus Research*, 13, 200234. <https://doi.org/10.1016/j.tvr.2021.200234>
- Cody, P., Tobe, K., Abe, M., & Elbasha, E. H. (2021). Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: A model-based study. *BMC Infectious Diseases*, 21(1), 11. <https://doi.org/10.1186/s12879-020-05632-0>
- Conway, E. L., Farmer, K. C., Lynch, W. J., Rees, G. L., Wain, G., & Adams, J. (2012). Quality of life valuations of HPV-associated cancer health states by the general population. *Sexually Transmitted Infections*, 88(7), 517–521. <https://doi.org/10.1136/sextrans-2011-050161>

- De Kok, I. M. C. M., Habbema, J. D. F., Van Rosmalen, J., & Van Ballegooijen, M. (2011). Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? *European Journal of Cancer*, 47(3), 428–435. <https://doi.org/10.1016/j.ejca.2010.09.030>
- De Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020). Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. *The Lancet Global Health*, 8(2), e180–e190. [https://doi.org/10.1016/S2214-109X\(19\)30488-7](https://doi.org/10.1016/S2214-109X(19)30488-7)
- De Sanjosé, S., Serrano, B., Tous, S., Alejo, M., Lloveras, B., Quirós, B., Clavero, O., Vidal, A., Ferrándiz-Pulido, C., Pavón, M. Á., Holzinger, D., Halc, G., Tommasino, M., Quint, W., Pawlita, M., Muñoz, N., Bosch, F. X., Alemany, L., RIS HPV TT, VVAP and Head and Neck study groups, & Kulkarni, A. (2018). Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58. *JNCI Cancer Spectrum*, 2(4), pky045. <https://doi.org/10.1093/jncics/pky045>
- Demarteau, N., Tang, C.-H., Chen, H.-C., Chen, C.-J., & Van Kriekinge, G. (2012). Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan. *Value in Health*, 15(5), 622–631. <https://doi.org/10.1016/j.jval.2012.02.012>
- Deng, Z.-J., Gui, L., Chen, J., Peng, S.-S., Ding, Y.-F., & Wei, A.-H. (2023). Clinical, economic and humanistic outcomes of medication therapy management services: A systematic review and meta-analysis. *Frontiers in Pharmacology*, 14, 1143444. <https://doi.org/10.3389/fphar.2023.1143444>
- Ding, W., Ma, Y., Ma, C., Malone, D. C., Ma, A., Tang, W., & Si, L. (2021). The lifetime cost estimation of human papillomavirus-related diseases in China: A modeling study. *Journal of Translational Internal Medicine*, 9(3), 200–211. <https://doi.org/10.2478/jtim-2021-0039>
- Direktorat Pengelolaan Imunisasi. (2023, November 7). *Kebijakan Imunisasi Antigen Baru di Indonesia (PCV, RV, dan HPV)*.
- Dragicevic, D., Andjelic, B., Jovic, R. M., Kljajic, V., & Savovic, S. (2019). Clinical stage of laryngeal carcinoma and lost time at the moment of diagnosis with 15-year-long interval. Are there any changes? *JBUON*, 24(5), 2041–2048.
- Forman, D., De Martel, C., Lacey, C. J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., Vignat, J., Ferlay, J., Bray, F., Plummer, M., & Franceschi, S. (2012). Global Burden of Human Papillomavirus and Related Diseases. *Vaccine*, 30, F12–F23. <https://doi.org/10.1016/j.vaccine.2012.07.055>

- GAVI. (2013, May 9). *Millions of girls in developing countries to be protected against cervical cancer thanks to new HPV vaccine deals*. <https://www.gavi.org/hpv-price-announcement>
- Graham, D. M., Isaranuwachai, W., Habbous, S., de Oliveira, C., Liu, G., Siu, L. L., & Hoch, J. S. (2015). A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer: Male HPV Vaccination for OPC Prevention. *Cancer*, 121(11), 1785–1792. <https://doi.org/10.1002/cncr.29111>
- HTA. (2017). *Health Technology Assessment (HTA) Guideline Indonesian Health Technology Assessment Committee (InaHTAC) Ministry of Health, Indonesia*. [https://adphealth.org/upload/resource/FINAL\\_HTA\\_ENG\\_1.pdf](https://adphealth.org/upload/resource/FINAL_HTA_ENG_1.pdf)
- HTA. (2018, November). *Hpv-evaluation-vaccine-programme-post-introduction-final-report-nov2018.pdf*. [https://www.who.int/docs/default-source/searo/indonesia/hpv-evaluation-vaccine-programme-post-introduction-final-report-nov2018.pdf?sfvrsn=9b63f1e9\\_2](https://www.who.int/docs/default-source/searo/indonesia/hpv-evaluation-vaccine-programme-post-introduction-final-report-nov2018.pdf?sfvrsn=9b63f1e9_2)
- IARC, W. (2020). *Global Cancer Observatory*. Global Cancer Observatory. <http://gco.iarc.fr/today/home>
- IARC, W. (2021, March). *Globocan 2020, Indonesia*. <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-factsheets.pdf>
- ICER. (2023). *Cost-Effectiveness, the QALY, and the evLYG*. Institute for Clinical and Economic Review. <https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/>
- Janiak-Kiszka, J., Nowaczewska, M., & Kaźmierczak, W. (2022). Oral squamous cell carcinoma—Clinical characteristics, treatment, and outcomes in a single institution retrospective cohort study. *Otolaryngologia Polska = The Polish Otolaryngology*, 76(3), 12–17. <https://doi.org/10.5604/01.3001.0015.7567>
- Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. *CA: A Cancer Journal for Clinicians*, 61(2), 69–90. <https://doi.org/10.3322/caac.20107>
- Kemenkes RI. (2023). *Permenkes Nomor 3 Tahun 2023 tentang Standar Tarif Pelayanan Kesehatan dalam Penyelenggaraan Jaminan Kesehatan*. Kementerian Kesehatan RI, Jakarta.

- Kemenkes RI. (2022, April 23). *Kemenkes Tambah 3 Jenis Vaksin Imunisasi Rutin, Salah Satunya HPV. Sehat Negeriku.* <https://sehatnegeriku.kemkes.go.id/baca/rilis-media/20220423/2939708/39708/>
- Kitano, T. (2022). Risk-Benefit Analysis of the 9-Valent HPV Vaccination for Adolescent Boys from an Individual Perspective. *Japanese Journal of Infectious Diseases*, 75(2), 114–120. <https://doi.org/10.7883/yoken.JJID.2021.367>
- Kosen, S., Andrijono, A., Ocviyanti, D., & Indriatmi, W. (2017). The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia. *Asian Pacific Journal of Cancer Prevention*, 18(7). <https://doi.org/10.22034/APJCP.2017.18.7.2011>
- Kristina, S. A., Endarti, D., & Aditama, H. (2022). Prediction of Productivity Costs Related to Cervical Cancer Mortality in Indonesia 2018. *Malaysian Journal of Medical Sciences*, 29(1), 138–144. <https://doi.org/10.21315/mjms2022.29.1.13>
- Luo, Y., He, H., Tang, X., Wang, S., Zhang, J., Wu, T., & Chen, Z. (2020). Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: Implications for China's expanded program on immunization. *Human Vaccines & Immunotherapeutics*, 16(7), 1623–1629. <https://doi.org/10.1080/21645515.2019.1711299>
- Mousavi, A., Yousefnezhad, A., Modarres-Gilani, M., Akhavan, S., & Sheikh-Hasani, S. (2019). Vulvar cancer in Iran: Retrospective study over 20 years (1998-2018). *Journal of Family Medicine and Primary Care*, 8(4), 1465–1469. [https://doi.org/10.4103/jfmpe.jfmpe\\_145\\_19](https://doi.org/10.4103/jfmpe.jfmpe_145_19)
- Myerson, R. J., Tan, B., Hunt, S., Olsen, J., Birnbaum, E., Fleshman, J., Gao, F., Hall, L., Kodner, I., Lockhart, A. C., Mutch, M., Naughton, M., Picus, J., Rigden, C., Safar, B., Sorscher, S., Suresh, R., Wang-Gillam, A., & Parikh, P. (2014). Five Fractions of Radiation Therapy Followed by 4 Cycles of FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. *International Journal of Radiation Oncology, Biology, Physics*, 88(4), 829–836. <https://doi.org/10.1016/j.ijrobp.2013.12.028>
- National Cancer Institute. (2019, March 1). *HPV and Cancer* (nciglobal,ncienterprise). <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer>
- National Cancer Institute. (2023, March 13). *Vaginal Cancer Treatment (PDQ®)—Health Professional Version* (nciglobal,ncienterprise). <https://www.cancer.gov/types/vaginal/hp/vaginal-treatment-pdq>

- NCCN. (2023a). *NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers*. National Comprehensive Cancer Network. [nccn.org](http://nccn.org)
- NCCN. (2023b). *NCCN Guidelines: Treatment by Cancer Type*. National Comprehensive Cancer Network. [https://www.nccn.org/guidelines/category\\_1](https://www.nccn.org/guidelines/category_1)
- NCI. (2019, March 1). *HPV and Cancer* (nciglobal,ncienterprise). National Cancer Institute. <https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hpv-and-cancer>
- Ndiaye, C., Mena, M., Alemany, L., Arbyn, M., Castellsagué, X., Laporte, L., Bosch, F. X., Sanjosé, S. de, & Trottier, H. (2014). HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. *The Lancet Oncology*, 15(12), 1319–1331. [https://doi.org/10.1016/S1470-2045\(14\)70471-1](https://doi.org/10.1016/S1470-2045(14)70471-1)
- NHS. (2019, July 31). *HPV vaccine*. Nhs.Uk. <https://www.nhs.uk/conditions/vaccinations/hpv-human-papillomavirus-vaccine/>
- Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, S., Hedrick, J., Jaisamrarn, U., Limson, G., Garland, S., Szarewski, A., Romanowski, B., Aoki, F., Schwarz, T., Poppe, W., ... Dubin, G. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. *The Lancet*, 374(9686), 301–314. [https://doi.org/10.1016/S0140-6736\(09\)61248-4](https://doi.org/10.1016/S0140-6736(09)61248-4)
- Patel, H., Chiva Giurca, B., Mukundu Nagesh, N., Hibell, I., Beattie, M., Saint, M., & Lau, G. (2019). Difficult Conversations in Cancer Care: Lessons from a Student-Led Initiative. *Journal of Cancer Education*, 34(6), 1242–1246. <https://doi.org/10.1007/s13187-019-01498-2>
- Patterson, R. H., Fischman, V. G., Wasserman, I., Siu, J., Shrim, M. G., Fagan, J. J., Koch, W., & Alkire, B. C. (2020). Global Burden of Head and Neck Cancer: Economic Consequences, Health, and the Role of Surgery. *Otolaryngology–Head and Neck Surgery*, 162(3), 296–303. <https://doi.org/10.1177/0194599819897265>
- Pearson, A. L., Kvizhinadze, G., Wilson, N., Smith, M., Canfell, K., & Blakely, T. (2014). Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: A cost-utility analysis in a country with



an existing school-girl program. *BMC Infectious Diseases*, 14, 351.  
<https://doi.org/10.1186/1471-2334-14-351>

Prigge, E. S., Von Knebel Doeberitz, M., & Reuschenbach, M. (2017). Clinical relevance and implications of HPV-induced neoplasia in different anatomical locations. *Mutation Research/Reviews in Mutation Research*, 772, 51–66. <https://doi.org/10.1016/j.mrrev.2016.06.005>

Priyadarshini, M., Prabhu, V. S., Snedecor, S. J., Corman, S., Kuter, B. J., Nwankwo, C., Chirovsky, D., & Myers, E. (2021). Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States. *Frontiers in Public Health*, 8, 624092. <https://doi.org/10.3389/fpubh.2020.624092>

Purba, F. D., Hunfeld, J. A. M., Iskandarsyah, A., Fitriana, T. S., Sadarjoen, S. S., Ramos-Goñi, J. M., Passchier, J., & Busschbach, J. J. V. (2017). The Indonesian EQ-5D-5L Value Set. *Pharmacoeconomics*, 35(11), 1153–1165. <https://doi.org/10.1007/s40273-017-0538-9>

Rai, M., & Goyal, R. (2018). Pharmacoeconomics in Healthcare. In *Pharmaceutical Medicine and Translational Clinical Research* (pp. 465–472). Elsevier. <https://doi.org/10.1016/B978-0-12-802103-3.00034-1>

Riskesdas. (2018). *Hasil Utama Riset Kesehatan Dasar 2018*. Kementerian Kesehatan Republik Indonesia. [https://kesmas.kemkes.go.id/assets/upload/dir\\_519d41d8cd98f00/files/Hasil-riskesdas-2018\\_1274.pdf](https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf)

Scheipner, L., Tappero, S., Piccinelli, M. L., Barletta, F., Garcia, C. C., Incesu, R.-B., Morra, S., Tian, Z., Saad, F., Shariat, S. F., Terrone, C., De Cobelli, O., Briganti, A., Chun, F. K. H., Tilki, D., Longo, N., Seles, M., Ahyai, S., & Karakiewicz, P. I. (2023). Differences in overall survival of penile cancer patients versus population-based controls. *International Journal of Urology: Official Journal of the Japanese Urological Association*. <https://doi.org/10.1111/iju.15346>

Setiawan, D., Andrijono, Hadinegoro, S. R., Meyta, H., Sitohang, R. V., Tandy, G., Perwitasari, D. A., & Postma, M. J. (2020). Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis. *PLOS ONE*, 15(3), e0230359. <https://doi.org/10.1371/journal.pone.0230359>

Setiawan, D., Dolk, F. C., Suwantika, A. A., Westra, T. A., Wilschut, J. C., & Postma, M. J. (2016). Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.

*Value in Health Regional Issues*, 9, 84–92.  
<https://doi.org/10.1016/j.vhri.2015.10.010>

Setiawan, D., Endarti, D., & Suwantika, A. A. (2017). *Farmakoekonomi Modelling*. UMP Press.

Sharma, S. J., Schartinger, V. H., Wuerdemann, N., Langer, C., Möllenhoff, K., Collin, L., Sutton, L., Riedl, D., Kreuter, A., Lechner, M., Wieland, U., & Klussmann, J. P. (2022). Awareness of Human Papillomavirus (HPV) and HPV Vaccination amongst the General Population in Germany: Lack of Awareness and Need for Action. *Oncology Research and Treatment*, 45(10), 561–567. <https://doi.org/10.1159/000525697>

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>

Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of pharmacist-led interventions. *Pharmacy Practice*, 19(1), 2302. <https://doi.org/10.18549/PharmPract.2021.1.2302>

Wahab, M. T., Tan, R. K. J., Cook, A. R., & Prem, K. (2023). Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis. *Vaccine*, 41(12), 1934–1942. <https://doi.org/10.1016/j.vaccine.2023.02.025>

WHO. (2023). *Human Papillomavirus (HPV)*. <https://www.who.int/teams/health-product-policy-and-standards/standards-and-specifications/vaccine-standardization/human-papillomavirus>

Wolff, E., Elfström, K. M., Haugen Cange, H., Larsson, S., Englund, H., Sparén, P., & Roth, A. (2018). Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. *Vaccine*, 36(34), 5160–5165. <https://doi.org/10.1016/j.vaccine.2018.07.018>

Wong, J., Allwright, M., Hruby, G., Roberts, J. M., Carr, A., Jin, F., Gett, R., Meagher, A. P., & Hillman, R. (2023). Anal cancer: A 20-year retrospective study from Australia. *ANZ Journal of Surgery*, 93(11), 2697–2705. <https://doi.org/10.1111/ans.18586>

Wu, X., Matanoski, G., Chen, V. W., Saraiya, M., Coughlin, S. S., King, J. B., & Tao, X.-G. (2008). Descriptive epidemiology of vaginal cancer incidence



and survival by race, ethnicity, and age in the United States. *Cancer*, 113(S10), 2873–2882. <https://doi.org/10.1002/cncr.23757>

YHEC. (2016a). *Markov Model*. York Health Economics Consortium. <http://yhec.co.uk/glossary/markov-model/>

YHEC. (2016b). *Sensitivity Analysis*. York Health Economics Consortium. <http://yhec.co.uk/glossary/sensitivity-analysis/>

YHEC. (2016c). *Time Horizon*. York Health Economics Consortium. <http://yhec.co.uk/glossary/time-horizon/>

YHEC. (2016d). *Utility*. York Health Economics Consortium. <https://yhec.co.uk/glossary/utility/>

YHEC, [online]. (2016e). *Cost-Effectiveness Threshold*. York Health Economics Consortium. <http://yhec.co.uk/glossary/cost-effectiveness-threshold/>

YHEC, [online]. (2016f). *Discount Rate*. York Health Economics Consortium. <http://yhec.co.uk/glossary/discount-rate/>